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Peroxisomal carbonyl reductase (PerCR), a tetrameric enzyme, enters peroxisomes when expressed in
human cells, but not when PerCR tetramers are introduced into these cells. The PerCR crystal structure
(Tanaka et al., 2008) yields insights that explain these data.
Pig heart peroxisomal carbonyl reductase
(PerCR) belongs to the short chain de-
hydrogenases/reductases (SDRs) family,
a large and diverse family of enzymes
found in bacteria, yeast, and multicellular
animals (Kallberg et al., 2002). The discov-
ery that enzymes that catalyzed the syn-
thesis or inactivation of steroid hormones,
such as estradiol, testosterone, and corti-
sol were SDRs, stimulated initial interest in
this protein family (Baker, 2001; Wu et al.,
2007). Currently, the PDB contains over
200 crystal structures of wild-type and
mutant SDRs cocrystallized with physio-
logical and synthetic substrates, and
much is known about the mechanism
of action of SDRs (Benach et al., 1998;
Tanaka et al., 1996; Wu et al., 2007).
SDRs have a catalytically active tyrosine,
which forms a triad with a highly con-
served lysine and serine at the catalytic
site. Of structural and functional impor-
tance is the presence of the catalytically
active tyrosine in a helix F, which has a
hydrophobic exterior surface, and along
with a helix E, forms the stabilizing intersu-
bunit interface (Benach et al., 1998;
Tanaka et al., 1996; Tsigelny and Baker,
1995) in SDR dimers and tetramers. With
one exception (Ghosh et al., 2001;
Tsigelny and Baker, 1995), all SDRs are
active as either dimers or tetramers.
Moreover, the exception contains an extra
segment with a hydrophobic a helix that
forms an ‘‘internal dimer interface’’ with
a helix F (Ghosh et al., 2001). It makes
sense that SDR monomers would be cat-
alytically inactive because exposure of the
hydrophobic surface of a helix F to water
would disrupt its structure and the config-
uration of the essential tyrosine in the
catalytic site (Tsigelny and Baker, 1995).
It would appear that with such an exten-
sive body of information about SDR
structure and function that there is not
much more to learn from these enzymes.
In this issue, however, studies by Tanaka
et al. (Tanaka et al., 2008) on pig heart
PerCR demonstrate that SDRs have
more to teach us about the relationship
between structure and biological mecha-
nisms, such as protein transport to organ-
elles. Moreover, Tanaka et al.’s report is
an excellent demonstration of the value
and, in this case, the necessity of having
the crystal structure of pig heart PerCR
to explain puzzling biochemical data,
and in the process uncover a novel mech-
anism for regulating the trafficking of olig-
omeric proteins to peroxisomes.
Pig heart PerCR localizes to peroxi-
somes, as expected in view of the SRL se-
quence at the carboxyl terminus (Tanaka
et al., 2008). SRL is a type 1 peroxisomal
targeting sequence (PTS1) and is a variant
of SKL, the canonical PTS1 (Leon et al.,
2006). SHL, another PTS1 variant, is at
the carboxyl terminus of dog liver PerCR.
Tanaka et al. (2008) undertook straightfor-
ward biochemical and molecular studies
to confirm that SRL functioned as a
PTS1 in pig PerCR by constructing SLL
and SL mutants, which are known to
lack PTS1 function (Maynard and Berg,
2007; Swinkels et al., 1992). Transfection
of HeLa cells with cDNA for pig PerCR,
or mutants with SLL and SL and with
SKL and SHL as controls, gave the ex-
pected results. The SLL and SL mutants
were not targeted to peroxisomes and
were enzymatically inactive. Only the
SKL and SHL mutants were targeted to
peroxisomes. Both mutants were enzy-
matically active, but the SKL variant was
less stable.
A distinguishing feature of protein
transport across the peroxisomal mem-
brane is that folded and oligomeric
proteins are transported across this
membrane, with or without noncova-
lently-bound cofactors (Subramani, 2002).
In fact, many peroxisomal proteins are
multimeric and several are known to
contain bound cofactors. If oligomeric
proteins are imported into peroxisomes,
then it follows that their PTSs must be
available for binding to the PTS receptors
in the oligomeric state. This is borne out
by binding studies showing that dimeric
dihydroxyacetone synthase DHAS (which
has the C-terminal sequence, NKL) can
indeed interact with Pex5 (PTS1 receptor)
from Hansenula polymorpha (Faber et al.,
2002).
Unexpectedly, introduction of the wild-
type pig PerCR tetramer directly into
HeLa cells did not lead to peroxisomal
localization (Tanaka et al., 2008). What
prevented the transport of pig PerCR to
the peroxisome? To answer this question,
Tanaka et al. (2008) crystallized pig PerCR
with NADPH. It is a homotetramer, with
a structure that resembles that of other
SDRs including a dimer interface consist-
ing of a helices E and F from each subunit.
Pig PerCR contains the triad of tyrosine,
lysine, and serine at the catalytic site.
Binding of the coenzyme NADPH to pig
PerCR resembles that of other SDRs. It
is the structure of the C-terminal SRL
that explains the perplexing observation
that introduction of pig PerCR protein
into HeLa cells does not lead to peroxi-
somal localization. The 3D structure
shows that SRL is at the tetramer inter-
face, where it is extensively structured
via hydrogen bonding, presumably shield-
ing the PTS1 from interactions with Pex5
(Tanaka et al., 2008). Tanaka et al. (2008)
propose that SRL is exposed to solvent
in the PerCR monomer, which would allow
binding to Pex5 and transport into the
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peroxisome, where PerCR would be
assembled into a tetramer.
Tanaka et al. (2008) also found that
while PerCR ending in SRL, SKL, or SHL
(all known from previous work to be func-
tional PTSs; Swinkels et al., 1992) were
imported into peroxisomes, PerCR end-
ing in SKL is unstable. Their 3D model of
this mutant suggests that replacement
of an R with a K in the intersubunit inter-
face reduces the stability of the tetramer.
These results suggest that in PerCR a bal-
ance has been reached between oligomer
stability, which is necessary for enzymatic
activity in the SDR family (Tsigelny and
Baker, 1995), and efficient peroxisomal
targeting, and that monomeric subunit
import is the solution that has evolved
without compromising protein stability
and activity.
The studies of Tanaka et al. (2008) may
be relevant to other multimeric proteins
that are not imported into peroxisomes,
but instead their monomeric subunits
are. The best-studied exemplar is alcohol
oxidase (AO) of methylotrophic yeasts,
which is an octameric protein. Monomers
of AO are imported into peroxisomes,
presumably because the PTS is indeed
available for Pex5 binding in these mono-
mers (Waterham et al., 1997). In contrast,
octameric AO is not imported into peroxi-
somes of H. polymorpha when the protein
is delivered into these cells by liposome
fusion (Douma et al., 2004). Binding stud-
ies confirmed that the octameric protein
did not bind to Pex5, whereas another
control protein, GFP-SKL, did (Faber
et al., 2002). However, in contrast to the
studies in the paper by Tanaka et al., the
structural basis for this presumed lack of
availability of the PTS in octameric AO is
unknown. Perhaps the crystal structure
of AO will yield another novel mechanism
for monomer import into peroxisomes.
REFERENCES
Baker, M.E. (2001). Mol. Cell. Endocrinol. 171,
211–215.
Benach, J., Atrian, S., Gonzalez-Duarte, R., and
Ladenstein, R. (1998). J. Mol. Biol. 282, 383–399.
Douma, A.C., Veenhuis, M., Driessen, A.J.M., and
Harder, W. (2004). Yeast 2004, 99–105.
Faber, K.N., van Dijk, R., Keizer-Gunnink, I., Koek,
A., van der Klei, I.J., and Veenhuis, M. (2002).
Biochim. Biophys. Acta 1591, 157–162.
Ghosh, D., Sawicki, M., Pletnev, V., Erman, M.,
Ohno, S., Nakajin, S., and Duax, W.L. (2001).
J. Biol. Chem. 276, 18457–18463.
Kallberg, Y., Oppermann, U., Jornvall, H., and
Persson, B. (2002). Protein Sci. 11, 636–641.
Leon, S., Goodman, J.M., and Subramani, S.
(2006). Biochim. Biophys. Acta 1763, 1552–1564.
Maynard, E.L., and Berg, J.M. (2007). J. Mol. Biol.
368, 1259–1266.
Subramani, S. (2002). J. Cell Biol. 156, 415–417.
Swinkels, B.W., Gould, S.J., and Subramani, S.
(1992). FEBS Lett. 305, 133–136.
Tanaka, N., Nonaka, T., Tanabe, T., Yoshimoto, T.,
Tsuru, D., and Mitsui, Y. (1996). Biochemistry 35,
7715–7730.
Tanaka, N., Aoki, K., Ishikura, S., Nagano, M.,
Imamura, Y., Hara, A., and Nakamura, K. (2008).
Structure 16, this issue, 388–397.
Tsigelny, I., and Baker, M.E. (1995). Biochem.
Biophys. Res. Commun. 217, 859–868.
Waterham, H.R., Russell, K.A., Vries, Y., and
Cregg, J.M. (1997). J. Cell Biol. 139, 1419–1431.
Wu, X., Lukacik, P., Kavanagh, K.L., and Opper-




1Departments of Protein Engineering and Antibody Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
*Correspondence: eigenbrot.c@gene.com
DOI 10.1016/j.str.2008.02.002
Qiu et al. (2008) add newweight to the very highly detailed understanding of how extracellular ligand binding-
induced dimerization of a receptor tyrosine kinase is first manifested inside the cell.
The ErbB family of receptor tyrosine
kinases has four members, all of which
are required for normal development.
The ErbB nomenclature arose from
homology to an avian erythroblastosis
gene— an alternate nomenclature derives
from similarity of the second identified hu-
man homolog, human epidermal growth
factor receptor-2 (HER2), to the first iden-
tified member, epidermal growth factor
receptor (EGFR, also HER1). Dysregula-
tion of one or more of these receptors is
associated with many cancers and thera-
peutic intervention has found wide appli-
cation. For instance, the anti-HER2 anti-
body trastuzumab (Herceptin) is the
standard of care for the subset of breast
cancers with HER2 overexpression, and
the anti-EGFR antibody cetuximab (Erbi-
tux) is used for metastatic colorectal
cancers. The therapeutic potential of
ATP-competitive inhibitors directed at
ErbB intracellular catalytic domains has
also been realized in erlotinib (Tarceva),
gefitinib (Iressa), and lapatinib (Ty-
kerb).
Most of these therapies were approved
during an ongoing eruption of structural
results that have helped rationalize their
mechanisms of action (Burgess et al.,
2003). The eruption started when X-ray
structures of the extracellular domain
(ECD) of EGFR with bound ligands, re-
ported by two groups in 2002, became
available (Garrett et al., 2002; Ogiso
et al., 2002). When these results were
combined with the contemporaneous
structure of the HER3 ECD with no bound
ligand (Cho and Leahy, 2002), it became
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